Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 3.1.6.12 - N-acetylgalactosamine-4-sulfatase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC3.1.6.12
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     3 Hydrolases
         3.1 Acting on ester bonds
             3.1.6 Sulfuric-ester hydrolases
                3.1.6.12 N-acetylgalactosamine-4-sulfatase
IUBMB Comments
Acts also on N-acetylglucosamine 4-sulfate.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Bacteria, Eukaryota
Synonyms
n-acetylgalactosamine-4-sulfatase, 4-sulfatase, 4-sulphatase, n-acetylgalactosamine 4-sulfatase, n-acetylgalactosamine-4-sulphatase, chondrosulfatase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4-sulfatase
-
-
4-sulphatase
-
-
acetylgalactosamine 4-sulfatase
-
-
-
-
arylsulfatase B
chondroitinase
-
-
-
-
chondroitinsulfatase
-
-
-
-
G4S
-
-
-
-
N-acetylgalactosamine 4-sulfatase
-
-
N-acetylgalactosamine 4-sulfate sulfohydrolase
-
-
-
-
N-acetylgalactosamine-4-sulfatase
N-acetylgalactosamine-4-sulphatase
-
-
sulfatase, acetylgalactosamine 4-
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of sulfuric ester
-
-
-
-
PATHWAY SOURCE
PATHWAYS
SYSTEMATIC NAME
IUBMB Comments
N-acetyl-D-galactosamine-4-sulfate 4-sulfohydrolase
Acts also on N-acetylglucosamine 4-sulfate.
CAS REGISTRY NUMBER
COMMENTARY hide
55354-43-3
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(2-acetamido-2-deoxy-O-(beta-D-glucuronic acid)-4-O-sulpho-D-galactose)2 + H2O
(2-acetamido-2-deoxy-O-(beta-D-glucuronic acid)-D-galactose)2 + sulfate
show the reaction diagram
-
exo-sulfatase, stepwise degradation of glycosaminoglycans
-
-
?
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferol + sulfate
show the reaction diagram
4-methylumbelliferyl sulfate + H2O
4-methylumbelliferone + sulfate
show the reaction diagram
4-methylumbelliferyl sulfate + H2O
sulfate + 4-methylumbelliferone
show the reaction diagram
-
-
-
?
4-nitrocatechol sulfate + H2O
4-nitrocatechol + sulfate
show the reaction diagram
-
-
-
-
?
chondroitin 4-sulfate + H2O
chondroitin + sulfate
show the reaction diagram
chondroitin 4-sulfate-heptasaccharide + H2O
chondroitin 4-sulfate-heptasaccharide + sulfate
show the reaction diagram
-
reduced activity in patients with Maroteaux-Lamy Syndrome
-
-
?
chondroitin 4-sulfate-tetrasaccharide + H2O
chondroitin 4-sulfate-tetrasaccharide + sulfate
show the reaction diagram
-
only the 4-sulfated endgroup is attacked by the enzyme, sulfate is released only in presence of beta-glucuronidase, acts as exosulphatase
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin sulfate + H2O
chondroitin + sulfate
show the reaction diagram
chondroitin-4-sulfate + H2O
chondroitin + sulfate
show the reaction diagram
-
arylsulfatase B removes 4-sulfate groups from the sulfated glycosaminoglycans chondroitin-4-sulfate and dermatan sulfate
-
-
?
dermatan sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
dermatan sulfate + H2O
dermatan + sulfate
show the reaction diagram
N-acetygalactosamine 4-sulfate-(1-4)-beta-glucuronic acid-(1-3)-beta-N-acetylgalactosaminitol 4-sulfate + H2O
N-acetygalactosamine-(1-4)-beta glucuronic acid-(1-3)-beta N-acetylgalactosaminitol 4-sulfate + sulfate
show the reaction diagram
-
oligosaccharides
-
-
?
N-acetyl-D-galactosamine 4-sulfate + H2O
N-acetyl-D-galactosamine + sulfate
show the reaction diagram
-
-
-
-
?
N-acetyl-D-galactosamine 4-sulfate units + H2O
N-acetyl-D-galactosamine units + sulfate
show the reaction diagram
-
acts also on N-acetylglucosamine 4-sulfate
-
-
?
N-acetylgalactosamine 4-sulfate + H2O
N-acetylgalactosamine + sulfate
show the reaction diagram
-
-
-
-
?
p-nitrocatechol sulfate + H2O
p-nitrocatechol + sulfate
show the reaction diagram
-
enzymes catalyze in addition to reaction of EC 3.1.6.12 also arylsulfatase reaction , see also EC 3.1.6.1
-
-
?
sulfated glycosaminoglycan + H2O
glycosaminoglycan + sulfate
show the reaction diagram
-
-
-
?
UDP-N-acetylgalactosamine-4-sulfate + H2O
UDP-N-acetylgalactosamine + sulfate
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
chondroitin sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
chondroitin-4-sulfate + H2O
chondroitin + sulfate
show the reaction diagram
-
arylsulfatase B removes 4-sulfate groups from the sulfated glycosaminoglycans chondroitin-4-sulfate and dermatan sulfate
-
-
?
dermatan sulfate + H2O
?
show the reaction diagram
-
-
-
-
?
dermatan sulfate + H2O
dermatan + sulfate
show the reaction diagram
-
arylsulfatase B removes 4-sulfate groups from the sulfated glycosaminoglycans chondroitin-4-sulfate and dermatan sulfate
-
-
?
N-acetyl-D-galactosamine 4-sulfate units + H2O
N-acetyl-D-galactosamine units + sulfate
show the reaction diagram
-
acts also on N-acetylglucosamine 4-sulfate
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Ca2+
-
-
chloride
-
affects the enzyme activity
Mg2+
-
stimulates
Mn2+
-
stimulates
phosphate
-
affects the enzyme activity
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
Ca2+
-
-
Cu2+
-
bivalent cations are inhibitory
iodoacetate
-
-
K2HPO4
-
-
Mg2+
-
-
Mn2+
-
slight
phosphate
-
-
vanadate
-
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
dithiothreitol
-
-
vanadate
maximal activation achieved for mutant arylsulfatase B C91S at highest vanadate concentration of 0.4 mM with concomitant irradation for 120 min
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.06
4-Methylumbelliferyl sulfate
-
pH 3.5
0.8 - 3.6
nitrocatechol sulfate
0.013
UDP-N-acetylgalactosamine 4-sulfate
-
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.00129
-
in cystic fibrosis N6 cells
0.00138
-
in cystic fibrosis IB3-1 cells
0.00193
-
in cystic fibrosis C38 cells
0.005
-
in cystic fibrosis C38 cells with 50% 1 M phosphate buffered saline in reaction mixture
0.282
-
-
93.3
-
nitrocatechol sulfate
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
3.5
-
UDP-N-acetylgalactosamine 4-sulfate
3.8
-
oligosaccharide substrate, formate buffer
4.4
-
oligosaccharide substrate, acetate buffer or dimethylglutarate buffer
5.3
-
wild-type and mutant enzyme
5.5
-
4-methylumbelliferyl sulfate
6.1
-
nitrocatechol sulfate
8.2
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
3 - 5
-
pH 3.0: about 85% of activity maximum, pH 5.0: about 15% of activity maximum
3.9 - 6.1
-
pH 3.9: about 40% of maximal activity, wild-type enzyme, pH 6.1: about 45% of maximal activity, wild-type enzyme. pH 3.9: about 40% of maximal activity, mutant enzyme Y210C, pH 6.1: about 45% of maximal activity, mutant enzyme Y210C
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
37
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
ARSB enzymatic activity is significantly greater in normal than in malignant tissue
Manually annotated by BRENDA team
-
ARSB enzymatic activity is significantly greater in normal than in malignant tissue
Manually annotated by BRENDA team
-
recombinant enzyme
Manually annotated by BRENDA team
-
-
Manually annotated by BRENDA team
compared to normal prostate cells or stroma, in malignant epithelium, expression of ARSB and Dickkopf Wnt Signaling Pathway Inhibitor DKK3 declines, and expression of galactose-6-sulfate-sulfatase and Wnt signaling targets increases
Manually annotated by BRENDA team
-
cultured fibroblasts
Manually annotated by BRENDA team
additional information
-
differences in distribution, intensity, and pattern of ARSB staining among normal colon, adenomas, and adenocarcinomas, overview. Distinctive, intense luminal membrane staining is present in the normal epithelial cells but reduced in the malignancies and less in the grade 3 than in the grade 1 adenocarcinomas. ARSB enzymatic activity is significantly greater in normal than in malignant tissue, detailed overview
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
additional information
-
extra-lysosomal enzyme localization
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
modification of expression of the enzyme regulates the content of chondroitin sulfate
physiological function
additional information
-
a relatively high rate of immunotolerance towards recombinant human N-acetylgalactosamine-4-sulfatase can be achieved in MPS-VI cats with a shortcourse tolerisation regimen ultimately permitting removal of lysosomal storage within the dura mater with the use of intrathecal therapy
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
ARSB_HUMAN
533
0
59687
Swiss-Prot
Secretory Pathway (Reliability: 2)
GALNS_HUMAN
522
0
58026
Swiss-Prot
other Location (Reliability: 1)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
13000
-
1 * 57000, composed of 2 peptides 1 * 43000, 1 * 13000
38000
-
1 * 38000, SDS-PAGE
43000
47000 - 54000
-
gel filtration
48000
-
gel filtration
57000
57000 - 61000
58000
-
SDS-PAGE
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
dimer
-
-
monomer
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
-
the wild-type enzyme has three N-glycosylation sites. Only oligosaccharides at the first, Asn158, and the third, Asn350, glycosylation site are phosphorylated, whereas the second, Asn184 is not
phosphoprotein
-
compared to degree of mannose-phosphorylation of the wild-type enzyme the mutant enzyme K457R has 33%, mutant enzyme K457S has 50%, mutant enzyme K457G has 31% mutant enzyme K433A has 95%, mutant enzyme K367A has 106% and mutant enzyme K393A has 123% of mannose-phosphorylation
proteolytic modification
-
33% of the intracellular Y210C mutant enzyme remains as a precursor form, for at least 8 h post labeling and is not processed to the mature lysosomal form. A significant amount of the mutant enzyme escapes the endoplasmic reticulum and is either secreted from the expression cells or undergoes delayed intracellular traffic. 67% of the intracellular Y210C mutant enzyme is processed to the mature form by a proteolytic processing step known to occur in lysosomes
additional information
conversion of an active-site cysteine into a formylglycine
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Ca2+ is bound to the active-site cysteine residue
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
C117R
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, severe phenotype
C192R
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, mild phenotype
C405Y
C447F
C447S
associated with the severe phenotype of mucopolysaccharidosis type VI
C521Y
C53S
-
the mutation causes ASB-deficiency, phenoytpe, overview. The enzyme is taken up into cultured ASB-deficient human fibroblasts, GM00519 cells, and translocates to the lysosomes, it is catalytically active. The enzyme enters target cells predominantly through the CI-M6P receptor. The uptake of rhASB is able to restore lysosomal function in an in vitro cell-based assay
D54N
associated with the severe phenotype of mucopolysaccharidosis type VI
D83Y
associated with the attenuated phenotype of mucopolysaccharidosis type VI
E421X
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, intermediate phenotype
G137V
G144R
G171D
associated with the attenuated phenotype of mucopolysaccharidosis type VI
G171S
associated with the attenuated phenotype of mucopolysaccharidosis type VI
G302R
G308R
-
mutant shows very low level of activity, the expressed mutation significantly reduces the amount of mature protein, the ARSB mutation has a significant effect on enzyme activity, protein processing and mRNA stability
H393P
H430R
associated with the attenuated phenotype of mucopolysaccharidosis type VI
I296N
associated with the severe phenotype of mucopolysaccharidosis type VI
K439E
associated with the severe phenotype of mucopolysaccharidosis type VI
K470A
-
mutation leads to an decrease of enzyme activity in the medium to 13% of total activity compared to 25% of the wild-type enzyme, no effect on phosphorylation
K470A/K497A/K507A
-
mutation leads to an decrease of enzyme activity in the medium to 17% of total activity compared to 25% of the wild-type enzyme, no effect on phosphorylation
K470A/K507A
-
mutation leads to an decrease of enzyme activity in the medium to 16% of total activity compared to 25% of the wild-type enzyme, no effect on phosphorylation
K497A
-
mutation leads to an decrease of enzyme activity in the medium to 19% of total activity compared to 25% of the wild-type enzyme, no effect on phosphorylation
K497A/K507A
-
mutation leads to an decrease of enzyme activity in the medium to 18% of total activity compared to 25% of the wild-type enzyme, no effect on phosphorylation
K507A
-
mutation leads to an decrease of enzyme activity in the medium to 23% of total activity compared to 25% of the wild-type enzyme, no effect on phosphorylation
L236P
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, second mutation C405Y, mild phenotype
L321P
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, intermediate phenotype
L360P
L472P
L498P
L72Q
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, heterozygote of L72Q and 219delC/221-230delCGCTGGCGGC on same allele and 743delC on other allele, severe phenotype
L72R
associated with the severe phenotype of mucopolysaccharidosis type VI
L82R
-
mutant shows very low level of activity, the expressed mutation significantly reduces the amount of mature protein, the ARSB mutation has a significant effect on enzyme activity, protein processing and mRNA stability
M142I
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, intermediate phenotype
P116H
P313A
-
mutant shows very low level of activity, the expressed mutation significantly reduces the amount of mature protein, the ARSB mutation has a significant effect on enzyme activity, protein processing and mRNA stability
P531R
Q456X
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, intermediate phenotype
Q503X
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, intermediate phenotype
R102H
associated with the attenuated phenotype of mucopolysaccharidosis type VI
R152W
R160Q
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, intermediate phenotype
R160X
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, intermediate phenotype
R315Q
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, intermediate phenotype
R315X
R434I
associated with the attenuated phenotype of mucopolysaccharidosis type VI
R513X
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, heterozygote of the R315X and Y513W alleles, severe phenotype
S240F
-
mutant shows very low level of activity, the expressed mutation significantly reduces the amount of mature protein, the ARSB mutation has a significant effect on enzyme activity, protein processing and mRNA stability
S320R
mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, homozygous, intermediate phenotype
S384N
T442M
associated with the attenuated phenotype of mucopolysaccharidosis type VI
T442R
associated with the attenuated phenotype of mucopolysaccharidosis type VI
W146L
W146R
W146S
W146X
second mutation Y210C, mutation in the arylsulfatase B gene responsible for mucopolysaccharidosis, intermediate phenotype
W353R
associated with the severe phenotype of mucopolysaccharidosis type VI
Y138C
-
mutant shows very low level of activity, the expressed mutation significantly reduces the amount of mature protein, the ARSB mutation has a significant effect on enzyme activity, protein processing and mRNA stability
Y210C
additional information
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
64
-
loss of activity
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
freezing, purified enzyme, rapid loss of activity, after 24 h irreversible
-
OXIDATION STABILITY
ORGANISM
UNIPROT
LITERATURE
photooxidation, with 1 mM Rose Bengal, 80% inactivation, no inactivation in presence of 1 mM pyridoxal phosphate and 30 mM 4-nitrocatechol
-
135544
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
mutant C91S purified on a anti-ASB affinity column prepared by coupling the antibody with NHS-sepharose beads
mutant enzyme C91S
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
ARSB, genotyping of wild-type and mutants
-
expressed in Escherichia coli
-
expression in CHO cells
-
expression in MCF-7 cells
expression in MCF-7 cells. Following overexpression of the enzyme, total sulfated glycosaminoglycans, chondroitin 4-sulfate, and chondroitin sulfates declines significantly
expression of ASB C53S mutant in CHO cells
-
mutant protein Y210C is expressed in CHO-K1 cells
-
mutants are expressed in COS-7 cells
-
overexpression in CHO-K1
wild-type and mutant enzymes transiently transfected into BHK cells
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
differences in distribution, intensity, and pattern of ARSB staining among normal colon, adenomas, and adenocarcinomas is shown. Distinctive, intense luminal membrane staining is present in the normal epithelial cells but reduced in the malignancies and less in the grade 3 than in the grade 1 adenocarcinomas. In the normal cores, a distinctive pattern of intense cytoplasmic positivity at the luminal surface is followed by reduced staining deeper in the crypts
-
exposure to 5alpha-dihydrotestosterone increases ARSB and DKK3 promoter methylation, resulting in decreased expression
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
diagnostics
-
altered ARSB immunostaining and reduced activity may be useful indicators of malignant transformation in human colonic tissue
medicine
additional information
-
a relatively high rate of immunotolerance towards recombinant human N-acetylgalactosamine-4-sulfatase can be achieved in MPS-VI cats with a shortcourse tolerisation regimen ultimately permitting removal of lysosomal storage within the dura mater with the use of intrathecal therapy
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Gibson, G.J.; Saccone, G.T.P.; Brooks, D.A.; Clements, P.R.; Hopwood, J.J.
Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values
Biochem. J.
248
755-764
1987
Homo sapiens
Manually annotated by BRENDA team
Agogbua, S.I.O.; Wynn, C.H.
Purification and properties of arylsulphatase B of human liver
Biochem. J.
153
415-421
1976
Homo sapiens
Manually annotated by BRENDA team
McGovern, M.M.; Vine, D.T.; Haskins, M.E.; Desnick, R.J.
Purification and properties of feline and human arylsulfatase B isozymes. Evidence for feline homodimeric and human monomeric structures
J. Biol. Chem.
257
12605-12610
1982
Felis catus, Homo sapiens
Manually annotated by BRENDA team
Fluharty, A.L.; Stevens, R.L.; Fung, D.; Peak, S.; Kihara, H.
Uridine diphospho-N-acetylgalactosamine-4-sulfate sulfohydrolase activity of human arylsulfatase B and its deficiency in the Maroteaux-Lamy syndrome
Biochem. Biophys. Res. Commun.
64
955-962
1975
Homo sapiens
Manually annotated by BRENDA team
Gorham, S.D.; Cantz, M.
Arylsulphatase B, an exo-sulphatase for chondroitin 4-sulphate tetrasaccharide
Hoppe-Seyler's Z. Physiol. Chem.
359
1811-1814
1978
Homo sapiens
Manually annotated by BRENDA team
Nicholls, R.G.; Roy, A.B.
Arylsulfatases
The Enzymes, 3rd Ed. (Boyer, P. D. , ed. )
5
21-41
1971
Bos taurus, Homo sapiens, Macropus sp.
-
Manually annotated by BRENDA team
Matalon, R.; Arbogast, B.; Dorfmann, A.
Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux-Lamy syndrome
Biochem. Biophys. Res. Commun.
61
1450-1457
1974
Homo sapiens
Manually annotated by BRENDA team
O'Brien, J.F.; Cantz, M.; Spranger, J.
Maroteaux-Lamy disease (mucopolysaccharidosis VI), subtype A: deficiency of a N-acetylgalactosamine-4-sulfatase
Biochem. Biophys. Res. Commun.
60
1170-1177
1974
Homo sapiens
Manually annotated by BRENDA team
Jin, T.; Kobayashi, T.; Honke, K.; Gasa, S.; Makita, A.
Use of immunoadsorbent column chromatography for improved purification of arylsulfatase B from human placenta
Biochem. Int.
26
1025-1033
1992
Homo sapiens
Manually annotated by BRENDA team
Brooks, D.A.; Gibson, G.J.; Hopwood, J.J.
Immunochemical characterization of feline and human N-acetylgalactosamine 4-sulfatase
Biochem. Med. Metab. Biol.
53
58-66
1994
Felis catus, Homo sapiens
Manually annotated by BRENDA team
Litjens, T.; Brooks, D.A.; Peters, C.; Gibson, G.J.; Hopwood, J.J.
Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients
Am. J. Hum. Genet.
58
1127-1134
1996
Homo sapiens
Manually annotated by BRENDA team
Bond, C.S.; Clements, P.R.; Ashby, S.J.; Collyer, C.A.; Harrop, S.J.; Hopwood, J.J.; Guss, J.M.
Structure of a human lysosomal sulfatase
Structure
5
277-289
1997
Homo sapiens
Manually annotated by BRENDA team
Yaghootfam, A.; Schestag, F.; Dierks, T.; Gieselmann, V.
Recognition of arylsulfatase A and B by the UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-phosphotransferase
J. Biol. Chem.
278
32653-32661
2003
Homo sapiens
Manually annotated by BRENDA team
Bradford, T.M.; Litjens, T.; Parkinson, E.J.; Hopwood, J.J.; Brooks, D.A.
Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network
Biochemistry
41
4962-4971
2002
Homo sapiens
Manually annotated by BRENDA team
Litjens, T.; Hopwood, J.J.
Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfate
Hum. Mutat.
18
282-295
2001
Homo sapiens (P15848), Homo sapiens
Manually annotated by BRENDA team
Christianson, T.M.; Starr, C.M.; Zankel, T.C.
Overexpression of inactive arylsulfatase mutants and in vitro activation by light-dependent oxidation with vanadate
Biochem. J.
382
581-587
2004
Homo sapiens (P15848)
Manually annotated by BRENDA team
Bhattacharyya, S.; Look, D.; Tobacman, J.K.
Increased arylsulfatase B activity in cystic fibrosis cells following correction of CFTR
Clin. Chim. Acta
380
122-127
2007
Homo sapiens
Manually annotated by BRENDA team
Bhattacharyya, S.; Kotlo, K.; Shukla, S.; Danziger, R.S.; Tobacman, J.K.
Distinct effects of N-acetylgalactosamine-4-sulfatase and galactose-6-sulfatase expression on chondroitin sulfates
J. Biol. Chem.
283
9523-9530
2008
Homo sapiens (P15848)
Manually annotated by BRENDA team
Auclair, D.; Hopwood, J.J.; Lemontt, J.F.; Chen, L.; Byers, S.
Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI
Mol. Genet. Metab.
91
352-361
2007
Homo sapiens
Manually annotated by BRENDA team
Saito, S.; Ohno, K.; Sugawara, K.; Sakuraba, H.
Structural and clinical implications of amino acid substitutions in N-acetylgalactosamine-4-sulfatase: Insight into mucopolysaccharidosis type VI
Mol. Genet. Metab.
93
419-425
2008
Homo sapiens (P15848)
Manually annotated by BRENDA team
Bhattacharyya, S.; Tobacman, J.K.
Arylsulfatase B regulates colonic epithelial cell migration by effects on MMP9 expression and RhoA activation
Clin. Exp. Metastasis
26
535-545
2009
Homo sapiens
Manually annotated by BRENDA team
Garrido, E.; Cormand, B.; Hopwood, J.J.; Chabas, A.; Grinberg, D.; Vilageliu, L.
Maroteaux-Lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase B gene
Mol. Genet. Metab.
94
305-312
2008
Homo sapiens
Manually annotated by BRENDA team
Harmatz, P.; Giugliani, R.; Schwartz, I.V.; Guffon, N.; Teles, E.L.; Miranda, M.C.; Wraith, J.E.; Beck, M.; Arash, L.; Scarpa, M.; Ketteridge, D.; Hopwood, J.J.; Plecko, B.; Steiner, R.; Whitley, C.B.; Kaplan, P.; Yu, Z.F.; Swiedler, S.J.; Decker, C.; Decker, C.
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
Mol. Genet. Metab.
94
469-475
2008
Homo sapiens
Manually annotated by BRENDA team
Bhattacharyya, S.; Solakyildirim, K.; Zhang, Z.; Chen, M.L.; Linhardt, R.J.; Tobacman, J.K.
Cell-bound IL-8 increases in bronchial epithelial cells after arylsulfatase B silencing due to sequestration with chondroitin-4-sulfate
Am. J. Respir. Cell Mol. Biol.
42
51-61
2010
Homo sapiens
Manually annotated by BRENDA team
Pungor, E.; Hague, C.M.; Chen, G.; Lemontt, J.F.; Dvorak-Ewell, M.; Prince, W.S.
Development of a functional bioassay for arylsulfatase B using the natural substrates of the enzyme
Anal. Biochem.
395
144-150
2009
Homo sapiens
Manually annotated by BRENDA team
Bhattacharyya, S.; Kotlo, K.; Danziger, R.; Tobacman, J.K.
Arylsulfatase B regulates interaction of chondroitin-4-sulfate and kininogen in renal epithelial cells
Biochim. Biophys. Acta
1802
472-477
2010
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Villani, G.R.; Grosso, M.; Pontarelli, G.; Chierchia, A.; Sessa, R.; Sibilio, M.; Parenti, G.; Di Natale, P.
Large deletion involving exon 5 of the arylsulfatase B gene caused apparent homozygosity in a mucopolysaccharidosis type VI patient
Genet. Test. Mol. Biomarkers
14
113-120
2010
Homo sapiens
Manually annotated by BRENDA team
Harmatz, P.; Yu, Z.F.; Giugliani, R.; Schwartz, I.V.; Guffon, N.; Teles, E.L.; Miranda, M.C.; Wraith, J.E.; Beck, M.; Arash, L.; Scarpa, M.; Ketteridge, D.; Hopwood, J.J.; Plecko, B.; Steiner, R.; Whitley, C.B.; Kaplan, P.; Swiedler, S.J.; Hardy, K.; Berger, K.I.; Decker, C.
Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
J. Inherit. Metab. Dis.
33
51-60
2010
Homo sapiens
Manually annotated by BRENDA team
Munoz-Rojas, M.V.; Horovitz, D.D.; Jardim, L.B.; Raymundo, M.; Llerena, J.C.; de Magalhaes, T.d.e..S.; Vieira, T.A.; Costa, R.; Kakkis, E.; Giugliani, R.
Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis
Mol. Genet. Metab.
99
346-350
2010
Homo sapiens
Manually annotated by BRENDA team
Prabhu, S.V.; Bhattacharyya, S.; Guzman-Hartman, G.; Macias, V.; Kajdacsy-Balla, A.; Tobacman, J.K.
Extra-lysosomal localization of arylsulfatase B in human colonic epithelium
J. Histochem. Cytochem.
59
328-335
2011
Homo sapiens
Manually annotated by BRENDA team
Auclair, D.; Finnie, J.; White, J.; Nielsen, T.; Fuller, M.; Kakkis, E.; Cheng, A.; ONeill, C.; Hopwood, J.
Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen
Mol. Genet. Metab.
99
132-141
2010
Homo sapiens
Manually annotated by BRENDA team
Bhattacharyya, S.; Feferman, L.; Tobacman, J.K.
Arylsulfatase B regulates versican expression by galectin-3 and AP-1 mediated transcriptional effects
Oncogene
33
5467-5476
2013
Homo sapiens (P34059)
Manually annotated by BRENDA team
Feferman, L.; Bhattacharyya, S.; Deaton, R.; Gann, P.; Guzman, G.; Kajdacsy-Balla, A.; Tobacman, J.K.
Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer
Prostate Cancer Prostatic. Dis.
16
277-284
2013
Homo sapiens
Manually annotated by BRENDA team
Ruane, T.; Haskins, M.; Cheng, A.; Wang, P.; Aguirre, G.; Knox, V.W.; Qi, Y.; Tompkins, T.; ONeill, C.A.
Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6 months of therapy in cats using different IV infusion durations
Mol. Genet. Metab.
117
157-163
2016
Homo sapiens (P15848), Homo sapiens
Manually annotated by BRENDA team
Mashima, R.; Ohira, M.; Okuyama, T.; Tatsumi, A.
Quantification of the enzyme activities of iduronate-2-sulfatase, N-acetylgalactosamine-6-sulfatase and N-acetylgalactosamine-4-sulfatase using liquid chromatography-tandem mass spectrometry
Mol. Genet. Metab. Rep.
14
36-40
2018
Homo sapiens
Manually annotated by BRENDA team
Bhattacharyya, S.; Feferman, L.; Tobacman, J.K.
Chondroitin sulfatases differentially regulate Wnt signaling in prostate stem cells through effects on SHP2, phospho-ERK1/2, and Dickkopf Wnt signaling pathway inhibitor (DKK3)
Oncotarget
8
242-260
2017
Homo sapiens (P15848), Homo sapiens
Manually annotated by BRENDA team
Bhattacharyya, S.; Feferman, L.; Tobacman, J.
Inhibition of phosphatase activity follows decline in sulfatase activity and leads to transcriptional effects through sustained phosphorylation of transcription factor MITF
PLoS ONE
11
e0153463
2016
Homo sapiens (P15848), Mus musculus (P50429)
Manually annotated by BRENDA team
Bhattacharyya, S.; Feferman, L.; Tobacman, J.
Dihydrotestosterone inhibits arylsulfatase B and Dickkopf Wnt signaling pathway inhibitor (DKK)-3 leading to enhanced Wnt signaling in prostate epithelium in response to stromal Wnt3A
Prostate
79
689-700
2019
Homo sapiens (P15848)
Manually annotated by BRENDA team
Bhattacharyya, S.; Feferman, L.; Tobacman, J.K.
Effect of CFTR modifiers on arylsulfatase B activity in cystic fibrosis and normal human bronchial epithelial cells
Pulm. Pharmacol. Ther.
36
22-30
2016
Homo sapiens (P15848)
Manually annotated by BRENDA team
Lin, W.D.; Ke, Y.Y.; Chou, I.C.; Wang, C.H.; Tsai, F.J.
Deletion of exon 4 in the N-acetylgalactosamine-4-sulfatase gene in a Taiwanese patient with mucopolysaccharidosis type VI
Tohoku J. Exp. Med.
235
267-273
2015
Homo sapiens (P15848), Homo sapiens
Manually annotated by BRENDA team